HK1223848A1 - 游離碱晶體 - Google Patents

游離碱晶體

Info

Publication number
HK1223848A1
HK1223848A1 HK16112288.8A HK16112288A HK1223848A1 HK 1223848 A1 HK1223848 A1 HK 1223848A1 HK 16112288 A HK16112288 A HK 16112288A HK 1223848 A1 HK1223848 A1 HK 1223848A1
Authority
HK
Hong Kong
Prior art keywords
free base
base crystals
crystals
free
base
Prior art date
Application number
HK16112288.8A
Other languages
English (en)
Inventor
Takashi Abe
Graham Buckton
Robert Davis
Mark Hooper
Peng Li
Hideaki Maruyama
Masahiro Takasuga
Lawrence P Wennogle
Yuhei Yamamoto
Hironori Yamashita
Original Assignee
Intra-Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra-Cellular Therapies Inc filed Critical Intra-Cellular Therapies Inc
Publication of HK1223848A1 publication Critical patent/HK1223848A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK16112288.8A 2013-06-21 2016-10-26 游離碱晶體 HK1223848A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US201361919424P 2013-12-20 2013-12-20
PCT/US2014/043422 WO2014205354A2 (en) 2013-06-21 2014-06-20 Free base crystals

Publications (1)

Publication Number Publication Date
HK1223848A1 true HK1223848A1 (zh) 2017-08-11

Family

ID=52105535

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112288.8A HK1223848A1 (zh) 2013-06-21 2016-10-26 游離碱晶體

Country Status (14)

Country Link
US (1) US9630971B2 (zh)
EP (2) EP3010509B1 (zh)
JP (2) JP6865036B2 (zh)
KR (2) KR20160040522A (zh)
CN (3) CN112851683A (zh)
AU (1) AU2014284224B2 (zh)
BR (1) BR112015032132B1 (zh)
CA (1) CA2916393C (zh)
ES (1) ES2894770T3 (zh)
HK (1) HK1223848A1 (zh)
IL (2) IL243269B (zh)
MX (2) MX2015017972A (zh)
RU (1) RU2675851C2 (zh)
WO (1) WO2014205354A2 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
WO2014205354A2 (en) 2013-06-21 2014-12-24 Takeda Pharmaceutical Company Limited Free base crystals
WO2021226407A1 (en) * 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Free base crystals
WO2023034965A2 (en) * 2021-09-03 2023-03-09 Intra-Cellular Therapies, Inc. Co-crystals
WO2023147484A1 (en) * 2022-01-27 2023-08-03 Intra-Cellular Therapies, Inc. Novel compositions
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US7425567B2 (en) * 2002-02-08 2008-09-16 Ono Pharmaceutical Co., Ltd. Piperidine derivative compounds and drugs containing the compounds as the active ingredient
EP1613747A1 (en) * 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
AU2004268024B2 (en) * 2003-09-02 2007-07-12 Merck Sharp & Dohme Llc Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
JP5154227B2 (ja) * 2004-09-27 2013-02-27 アカディア ファーマシューティカルズ インコーポレイテッド N−(4−フルオロベンジル)−n−(1−メチルピペリジン−4−イル)−n’−(4−(2−メチルプロピルオキシ)フェニルメチル)カルバミドの塩及びその調製
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
ES2411604T3 (es) 2006-11-13 2013-07-05 Intra-Cellular Therapies, Inc. Compuestos orgánicos
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
DK2240490T3 (da) 2007-12-06 2013-12-16 Takeda Pharmaceutical Organiske forbindelser
EP2370080A1 (en) * 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
SG171776A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
CN102238872A (zh) 2008-12-06 2011-11-09 细胞内治疗公司 有机化合物
ES2638912T3 (es) 2008-12-06 2017-10-24 Intra-Cellular Therapies, Inc. Compuestos orgánicos
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE 1 INHIBITOR FOR OPHTHALMIC DISORDERS
JP2012526810A (ja) * 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US8858911B2 (en) 2009-10-08 2014-10-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
AR091507A1 (es) * 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
WO2014205354A2 (en) 2013-06-21 2014-12-24 Takeda Pharmaceutical Company Limited Free base crystals

Also Published As

Publication number Publication date
IL243269A0 (en) 2016-02-29
JP2016523258A (ja) 2016-08-08
CA2916393A1 (en) 2014-12-24
US20160145261A1 (en) 2016-05-26
ES2894770T3 (es) 2022-02-15
RU2016101630A3 (zh) 2018-03-21
EP3010509B1 (en) 2021-07-28
JP6865036B2 (ja) 2021-04-28
JP2019189618A (ja) 2019-10-31
MX2020001628A (es) 2020-07-13
CN105658222A (zh) 2016-06-08
KR102430126B1 (ko) 2022-08-05
CN110498800A (zh) 2019-11-26
WO2014205354A2 (en) 2014-12-24
BR112015032132B1 (pt) 2022-03-15
EP3010509A2 (en) 2016-04-27
BR112015032132A2 (pt) 2017-07-25
KR20160040522A (ko) 2016-04-14
WO2014205354A3 (en) 2015-05-28
RU2016101630A (ru) 2017-07-26
AU2014284224B2 (en) 2019-08-01
US9630971B2 (en) 2017-04-25
EP3010509A4 (en) 2016-11-23
RU2675851C2 (ru) 2018-12-25
IL243269B (en) 2019-06-30
MX2015017972A (es) 2016-10-28
EP3702358A1 (en) 2020-09-02
CA2916393C (en) 2022-03-22
KR20210122890A (ko) 2021-10-12
CN112851683A (zh) 2021-05-28
IL267331A (en) 2019-08-29
AU2014284224A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
IL246002A0 (en) New methods
GB201413149D0 (en) No details
AU353440S (en) Watch
HK1217367A1 (zh) 鐘錶
EP3050254A4 (en) MULTI-FOYER SUPPORT
HK1214224A1 (zh) 新穎的器件
IL267331A (en) Crystals of a compound in the free state
AU355563S (en) Wristwatch
GB201410903D0 (en) No details
GB201418212D0 (en) No details
AU351857S (en) Watch
AU350512S (en) Wristwatch
GB201418129D0 (en) No details
GB201408089D0 (en) No details
GB201416327D0 (en) No details
HK1204451A1 (zh) 新用途
GB201407200D0 (en) No details
PL2944730T3 (pl) Miska ustępowa sedesu
GB201417843D0 (en) No details
GB201322664D0 (en) Support
GB201404510D0 (en) Crystal structure
GB201320608D0 (en) Novel Device
GB201321223D0 (en) Novel use
GB201321218D0 (en) Novel use
GB201312554D0 (en) Novel device